{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:31:44Z","timestamp":1774528304373,"version":"3.50.1"},"reference-count":48,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background and Objectives: Alcoholic hepatitis (AH) is a growing public health concern with its rising incidence and its contribution to nearly half of all cirrhosis-related deaths in the United States. In this systematic review, we aimed to comprehensively evaluate the current evidence and trials on the use of anti-interleukin-1 (anti-IL-1) drugs in patients with AH, assessing their efficacy and adverse events compared to routinely prescribed drugs like corticosteroids. Materials and Methods: A comprehensive literature search was conducted across five databases to identify randomized controlled trials (RCTs) evaluating the role of anti-IL-1 agents like canakinumab and anakinra among patients diagnosed with AH. Data was extracted and pooled in the form of mean and standard deviation for continuous variables and event and total for dichotomous variables. Results: Three RCTs were included for quantitative synthesis, encompassing 307 patients. Using canakinumab, 58% of patients showed improvement in histology. Prednisolone was associated with higher 90-day survival (90% vs. 70%; hazard ratio for death = 0.34, 95% CI 0.14\u20130.83, p = 0.018) and transplant-free survival. Overall, a higher incidence of acute kidney injury and new-onset cardiac disorders was noted in the anti-IL-1 arm when compared to placebo. Conclusions: This study concludes the lack of efficacy of anti-IL-1 agents in causing improvement in patient outcomes when compared to standard therapies. A higher incidence of adverse events was also noted in the anti-IL-1 arm. These results emphasize the need for future clinical trials to evaluate the use of anti-IL-1 agents in AH objectively.<\/jats:p>","DOI":"10.3390\/life15071106","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:01:05Z","timestamp":1752591665000},"page":"1106","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing Efficacy of Interleukin-1 Blockade in Patients with Alcoholic Hepatitis: A Comprehensive Systematic Review of Emerging Evidence"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4273-0827","authenticated-orcid":false,"given":"Shree","family":"Rath","sequence":"first","affiliation":[{"name":"All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar 751019, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1740-887X","authenticated-orcid":false,"given":"Mary","family":"Girgis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Cairo University, Cairo 12613, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-5404","authenticated-orcid":false,"given":"Ishita","family":"Gupta","sequence":"additional","affiliation":[{"name":"St. Bernards Medical Center, Jonesboro, AR 72401, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anchit","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Maulana Azad Medical College, Delhi 110002, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9613-3614","authenticated-orcid":false,"given":"Zahir","family":"Ud Din","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar 25120, KPK, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Hotchandani","sequence":"additional","affiliation":[{"name":"SUNY Upstate Medical University, Syracuse, NY 13210, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Hasan","sequence":"additional","affiliation":[{"name":"Imperial College London, London W12 0NN, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2814-7314","authenticated-orcid":false,"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raheel","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Queen Elizabeth Hospital, Gateshead NE9 6SX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14309\/ajg.0000000000000442","article-title":"Rising mortality from alcohol-associated liver disease in the united states in the 21st century","volume":"115","author":"Moon","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/alcalc\/agz036","article-title":"Alcoholic hepatitis: A review","volume":"54","author":"Hosseini","year":"2019","journal-title":"Alcohol Alcohol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: Management of alcohol-related liver disease","volume":"69","author":"Thursz","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2009.04002.x","article-title":"Review article: The diagnosis and management of alcoholic hepatitis","volume":"30","author":"Cohen","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_5","unstructured":"(2018). Global Status Report on Alcohol and Health 2018, World Health Organization. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2514857","DOI":"10.1001\/jamanetworkopen.2025.14857","article-title":"Alcohol-associated liver disease mortality","volume":"8","author":"Pan","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MCG.0000000000000161","article-title":"Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the united states","volume":"49","author":"Jinjuvadia","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1097\/MCG.0000000000001627","article-title":"The pandemic within the pandemic: Unprecedented rise in alcohol-related hepatitis during the COVID-19 pandemic","volume":"56","author":"Sohal","year":"2022","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2210259","DOI":"10.1001\/jamanetworkopen.2022.10259","article-title":"Evaluation of trends in alcohol use disorder\u2013related mortality in the us before and during the COVID-19 pandemic","volume":"5","author":"Yeo","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the niaaa alcoholic hepatitis consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1572-0241.1999.01006.x","article-title":"The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease","volume":"94","author":"Sorbi","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/alcalc\/agh074","article-title":"High ast\/alt ratio may indicate advanced alcoholic liver disease rather than heavy drinking","volume":"39","author":"Nyblom","year":"2004","journal-title":"Alcohol Alcohol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gut.2010.224097","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: Meta-analysis of individual patient data","volume":"60","author":"Mathurin","year":"2011","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ajg.2016.539","article-title":"A day-4 lille model predicts response to corticosteroids and mortality in severe alcoholic hepatitis","volume":"112","author":"Duvoor","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0037-1608788","article-title":"Clinical trial design for alcoholic hepatitis","volume":"37","author":"Szabo","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jceh.2022.06.012","article-title":"Emerging pharmacotherapies in alcohol-associated hepatitis","volume":"13","author":"Wakil","year":"2023","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/hep.24256","article-title":"Hepatocyte-specific hypoxia-inducible factor-1\u03b1 is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice","volume":"53","author":"Nath","year":"2011","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/710381","article-title":"Toll-like receptors in the pathogenesis of alcoholic liver disease","volume":"2010","author":"Petrasek","year":"2010","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000341126","article-title":"Innate immunity and alcoholic liver disease","volume":"30","author":"Szabo","year":"2012","journal-title":"Dig. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1084\/jem.20122006","article-title":"IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells","volume":"210","author":"Hogg","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1038\/s41467-018-05489-7","article-title":"T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells","volume":"9","author":"Jain","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/0024-3205(86)90554-0","article-title":"Serum interleukin-1 (IL-1) activity in alcoholic hepatitis","volume":"39","author":"McClain","year":"1986","journal-title":"Life Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e95354","DOI":"10.1172\/jci.insight.95354","article-title":"Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: Exploiting similarities and differences in pathogenesis","volume":"2","author":"Greuter","year":"2017","journal-title":"JCI Insight"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1172\/JCI60777","article-title":"IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice","volume":"122","author":"Petrasek","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/liv.13430","article-title":"Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice","volume":"37","author":"Petrasek","year":"2017","journal-title":"Liver Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","article-title":"Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis","volume":"80","author":"Gawrieh","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cgh.2024.07.025","article-title":"Il-1 signal inhibition in alcohol-related hepatitis: A randomized, double-blind, placebo-controlled trial of canakinumab","volume":"23","author":"Vergis","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.livres.2018.03.003","article-title":"Cytokines and fatty liver diseases","volume":"2","author":"Niederreiter","year":"2018","journal-title":"Liver Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.jceh.2022.05.004","article-title":"Pathogenesis of alcohol-associated liver disease","volume":"12","author":"Osna","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4254\/wjh.v12.i7.332","article-title":"Oxidative stress in alcohol-related liver disease","volume":"12","author":"Tan","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Jia, Y., and Zhang, E. (2025). Oxidative stress modulation in alcohol-related liver disease: From chinese botanical drugs to exercise-based interventions. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1516603"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/gut.20.12.1109","article-title":"Corticosteroids in liver disease: Possible mechanisms of action, pharmacology, and rational use","volume":"20","author":"Tanner","year":"1979","journal-title":"Gut"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhong, W., Sun, Q., and Zhou, Z. (2016). Role of zinc in alcoholic liver disease. Molecular Aspects of Alcohol and Nutrition, Elsevier.","DOI":"10.1016\/B978-0-12-800773-0.00012-4"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jhep.2018.11.005","article-title":"Endpoints and patient stratification in clinical trials for alcoholic hepatitis","volume":"70","author":"Mathurin","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101352","DOI":"10.1016\/j.jcmgh.2024.04.009","article-title":"Inflammation in alcohol-associated hepatitis: Pathogenesis and therapeutic targets","volume":"18","author":"Feng","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41232-019-0101-5","article-title":"The role of interleukin-1 in general pathology","volume":"39","author":"Kaneko","year":"2019","journal-title":"Inflamm. Regen."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2024.03.031","article-title":"Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (Adqi) and International Club of Ascites (Ica) joint multidisciplinary consensus meeting","volume":"81","author":"Nadim","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4254\/wjh.v15.i8.954","article-title":"Prognostic and diagnostic scoring models in acute alcohol-associated hepatitis: A review comparing the performance of different scoring systems","volume":"15","author":"Mitri","year":"2023","journal-title":"World J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1007\/s10620-024-08479-6","article-title":"Utility of lille score in predicting 30-day survival in steroid-treated alcohol-associated hepatitis","volume":"69","author":"Healey","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease","volume":"70","author":"Nahon","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41416-020-01031-z","article-title":"Alcohol drinking and head and neck cancer risk: The joint effect of intensity and duration","volume":"123","author":"Polesel","year":"2020","journal-title":"Br. J. Cancer"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1106\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:12Z","timestamp":1760033412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["life15071106"],"URL":"https:\/\/doi.org\/10.3390\/life15071106","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}